Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006747 | 0.81 | KDM4E (0.55) | NPSR1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL1857463 | 0.75 | NPSR1 (1.00) | NPSR1KMT2AMEN1KDM4EADORA3 | |
| SCHEMBL7244568 | 0.75 | NPSR1 (0.95) | NPSR1KMT2AMEN1KDM4EADORA3 | |
| SCHEMBL1857317 | 0.72 | NPSR1 (0.65) | NPSR1KMT2AMEN1KDM4EADORA3 | |
| SCHEMBL6987780 | 0.72 | NPSR1 (0.63) | NPSR1KMT2AMEN1KDM4EADORA3 | |
| SCHEMBL7063434 | 0.70 | CCNC (0.71) | NPSR1KMT2AMEN1KDM4EADORA3 | |
| SCHEMBL7246971 | 0.70 | KDM4E (0.55) | NPSR1KMT2AMEN1KDM4EADORA3 | |
| SCHEMBL7249137 | 0.70 | NPSR1 (0.55) | NPSR1KMT2AMEN1KDM4EADORA3 | |
| SCHEMBL7249139 | 0.70 | NPSR1 (0.55) | NPSR1KMT2AMEN1KDM4EADORA3 | |
| SCHEMBL7243279 | 0.69 | NPSR1 (0.60) | NPSR1KMT2AMEN1KDM4EADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | NPSR1 95/4885KMT2A 1139/4885MEN1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.